226 related articles for article (PubMed ID: 11924798)
41. [Application and recent advances of laboratory mouse in human cancer research].
Liu EQ; Kitajima S; Morimoto M
Ai Zheng; 2005 Feb; 24(2):249-54. PubMed ID: 15694046
[TBL] [Abstract][Full Text] [Related]
42. Current and future approaches using genetically modified mice in endocrine research.
Davey RA; MacLean HE
Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E429-38. PubMed ID: 16684850
[TBL] [Abstract][Full Text] [Related]
43. The use of biotechnical recombinant-mice to test the safety of potential carcinogenic pharmaceuticals.
Inoue T
J Toxicol Sci; 1995 Sep; 20(4):468-70. PubMed ID: 8531244
[No Abstract] [Full Text] [Related]
44. Primer for non-immunologists on immune-deficient mice and their applications in research.
Croy BA; Linder KE; Yager JA
Comp Med; 2001 Aug; 51(4):300-13. PubMed ID: 11924787
[TBL] [Abstract][Full Text] [Related]
45. Impact of brain-behavior phenotypying of genetically-engineered mice on research of neuropsychiatric disorders.
Takao K; Yamasaki N; Miyakawa T
Neurosci Res; 2007 Jun; 58(2):124-32. PubMed ID: 17524507
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
Kirkland D; Aardema M; Henderson L; Müller L
Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
[TBL] [Abstract][Full Text] [Related]
47. Mouse nomenclature and maintenance of genetically engineered mice.
Linder CC
Comp Med; 2003 Apr; 53(2):119-25. PubMed ID: 12784845
[TBL] [Abstract][Full Text] [Related]
48. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
[TBL] [Abstract][Full Text] [Related]
49. The stress or heat shock (HS) response: insights from transgenic mouse models.
Christians ES; Benjamin IJ
Methods; 2005 Feb; 35(2):170-5. PubMed ID: 15649844
[TBL] [Abstract][Full Text] [Related]
50. The utility of the K6/ODC transgenic mouse as an alternative short term dermal model for carcinogenicity testing of pharmaceuticals.
Miller TJ; Honchel R; Espandiari P; Knapton A; Zhang J; Sistare FD; Hanig JP
Regul Toxicol Pharmacol; 2008 Feb; 50(1):87-97. PubMed ID: 18069108
[TBL] [Abstract][Full Text] [Related]
51. Pathogenesis of myelofibrosis with myeloid metaplasia: lessons from mouse models of the disease.
Vannucchi AM; Migliaccio AR; Paoletti F; Chagraoui H; Wendling F
Semin Oncol; 2005 Aug; 32(4):365-72. PubMed ID: 16202682
[TBL] [Abstract][Full Text] [Related]
52. Development of human cell models for assessing the carcinogenic potential of chemicals.
Pang Y; Li W; Ma R; Ji W; Wang Q; Li D; Xiao Y; Wei Q; Lai Y; Yang P; Chen L; Tang S; Lin Y; Zhuang Z; Zheng Y; Chen W
Toxicol Appl Pharmacol; 2008 Nov; 232(3):478-86. PubMed ID: 18778725
[TBL] [Abstract][Full Text] [Related]
53. Mouse models for human head and neck squamous cell carcinomas.
Lu SL; Herrington H; Wang XJ
Head Neck; 2006 Oct; 28(10):945-54. PubMed ID: 16721744
[TBL] [Abstract][Full Text] [Related]
54. Animal models in biomedical research: transgenesis and gene targeting.
Roes J
Br J Hosp Med; 1997 Apr 16-May 6; 57(8):410-1. PubMed ID: 9274667
[No Abstract] [Full Text] [Related]
55. [Development of animal models for carcinogenesis by transgenesis. Transgenic mouse models for cancer research].
Katsuki M
Jikken Dobutsu; 1993 Jul; 42(3):281-2. PubMed ID: 8354348
[No Abstract] [Full Text] [Related]
56. [Molecular models of disease. Transgenes and knockout].
Moradpour D
Dtsch Med Wochenschr; 1997 Dec; 122(49):1527-30. PubMed ID: 9453919
[No Abstract] [Full Text] [Related]
57. Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.
Urano K; Tamaoki N; Nomura T
Vet Pathol; 2012 Jan; 49(1):16-23. PubMed ID: 22146850
[TBL] [Abstract][Full Text] [Related]
58. In vivo transgenic bioassays and assessment of the carcinogenic potential of pharmaceuticals.
Contrera JF; DeGeorge JJ
Environ Health Perspect; 1998 Feb; 106 Suppl 1(Suppl 1):71-80. PubMed ID: 9539006
[TBL] [Abstract][Full Text] [Related]
59. Evaluation and validation issues in the development of transgenic mouse carcinogenicity bioassays.
Tennant RW
Environ Health Perspect; 1998 Apr; 106 Suppl 2(Suppl 2):473-6. PubMed ID: 9599694
[TBL] [Abstract][Full Text] [Related]
60. Alternatives models in carcinogenicity testing--a European perspective.
van der Laan J; Lima BS; Snodin D
Toxicol Pathol; 2002; 30(1):157-9. PubMed ID: 11890470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
